MyoKardia is a Transformative Therapies company. It is applying a precision medicine approach to develop therapeutic candidates for patient populations with shared characteristics such as causal genetic mutations or disease subtypes. The headquarters is in USA.
Bristol Myers Squibb acquired MyoKardia for 13.1 Billion USD in Nov-2020.